61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
AbbVie Inc
Open
Sector Healthcare
176.46 -2.84
Overview
Share price change
24h
Min
175.89
Max
181.4
Income | 191M 1.6B |
|---|---|
Sales | 14B |
P/E Sector Avg | 51.05 94.904 |
EPS | 3 |
Dividend yield | 3.14 |
Profit margin | 10.795 |
Employees | 50,000 |
EBITDA | 1B 6B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +13.02 upside |
Dividend yield Sector Avg | 3.14% 2.43% |
|---|---|
Next Earnings | 31 Jan 2025 |
Next Dividend date | 13 Feb 2025 |
Next Ex Dividend date | 13 Jan 2025 |
Market Cap | -7.2B 317B |
|---|---|
Previous open | 179.3 |
Previous close | 176.46 |
News Sentiment
By Acuity
20%
80%
39 / 392 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
AbbVie Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
AbbVie Inc Forecast
Price Target
By TipRanks
13.02% upside
12 Months Forecast
Average 205.44 USD 13.02%
High 240 USD
Low 165 USD
Based on 19 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.
Sentiment
By Acuity
39 / 392 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AbbVie Inc
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.
